← Metformin × all-cause mortality

SynthesisMedicine2022

Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies.

Jing Yang et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with fewer deaths

−21%−27% to −14%

Bigger than 6 in 10 for all-cause mortality

As reported

HR 0.79, 95% CI 0.73–0.86 · the paper's word: All-cause mortality

Correlation, not cause

Went with fewer deaths

−24%−34% to −13%

Bigger than 7 in 10 for all-cause mortality

As reported

HR 0.76, 95% CI 0.66–0.87 · the paper's word: All-cause mortality

Two numbers in the abstract

the abstract, start to end

… and cancer-specific survival (HR = 0.79; 95% CI: [0.73-0.86]), and metformin was associated with progression-free survival (HR = 0.76; 95% CI: [0.66-0.87]).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
HR 0.790.73–0.86
All-cause mortality
HR 0.760.66–0.87
MetforminAll-cause mortality
1 / 3

10 papers cite it

2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 36626437